MOLINA HEALTHCARE, INC. MOH

Molina Healthcare’s Illinois subsidiary just landed a Medicaid managed care contract from the state’s Department of Healthcare and Family Services, a deal that hands Molina another slice of the state’s HealthChoice Illinois program and adds real revenue visibility to a balance sheet that otherwise looks like a spreadsheet designed by someone colour-blind to red ink. The award lands on the same day Molina’s latest 10-Q shows $10.80 billion in revenue for the quarter ending 31 March 2026, but only $14.0 million in net income, a figure that shrinks to a $69 million loss if you strip out a timing quirk in Medicare revenue recognition. The optics are awkward: a company that can’t turn a profit without accounting alchemy just won a government contract that might rescue its top line.

Molina is a Fortune 500 insurer specialising in government-sponsored health plans across Medicaid, Medicare, and ACA markets, selling managed care products to low-income and senior populations in 19 states. The company’s core product is the Medicaid managed care plan: it contracts with states to provide comprehensive health coverage, coordinates care through provider networks, and shoulders the actuarial risk of enrollee utilisation. The Illinois win is material because the state’s Medicaid programme serves roughly 3 million residents, and Molina’s existing footprint there already gives it a head start in competing for the HealthChoice Illinois award. The contract is not a licence to print cash; it’s a licence to spend cash on claims while hoping the state’s reimbursement rates cover the gap between premiums and medical costs.

Filings paint a balance sheet that is liquid but levered: as of 31 March 2026, Molina reported $16.39 billion in total assets and $12.31 billion in liabilities, leaving shareholders with $4.08 billion in equity. Cash and equivalents stood at $5.31 billion, up from the year-ago quarter, while net cash from operating activities clocked in at $1.08 billion. Operating income of $83.0 million on $10.80 billion in revenues is thin-0.77% margin-and the company’s diluted EPS of $0.27 for the quarter is a rounding error compared to the size of the balance sheet. Capital expenditure for the period was $27.0 million, modest relative to cash flow but a reminder that running managed care networks requires more than actuarial models: it requires clinics, providers, and IT systems that actually work on Monday mornings.

The company’s SEC traffic in May and June 2026 reads like a season of insider-filing binge: Form 4s, 144s, an S-8 registration, and a 13G filing all hit the tape within days of each other, a cadence that looks less like organic investor interest and more like a management desks rehearsing its next act. The 8-K filed on 10 June 2026 explicitly states the Illinois award, but the filings trail also includes an 8-K from 8 May 2026 teasing Investor Day targets for 2029 premium revenue and adjusted EPS, and an 8-K from 11 May 2026 summarising a 2025 Plan Amendment-details that invite questions about whether the Illinois win is a genuine inflection or merely a salve for a balance sheet that hasn’t turned a clean quarter since the calendar flipped to 2026.

If you want a chart, the TradingView route for MOH is a reliable place to watch the tape, but the company’s filings do not supply a neat revenue-by-geography breakdown that would let outsiders map the Illinois contract to a visible EPS uplift. What is visible is that Molina’s Illinois subsidiary now has a state contract with clear enrollee minimums and capitated payments, but the actual contract terms-and the timing of enrollee start dates-are not disclosed in the 8-K, so the revenue ramp remains a black box. The market will have to trust the filings’ promises of future growth while the present facts sit on the balance sheet like an unpaid invoice.

What changed this week: Molina’s Illinois subsidiary secured a Medicaid managed care contract from the Illinois Department of Healthcare and Family Services, announced 10 June 2026. What has not changed: the company’s thin operating margins, its leverage ratio, and the opacity around how much of the Illinois contract’s economics will actually wash through to net income. The evidence does not supply enrollee minimums, start dates, or capitation rates for the Illinois award, and the 10-Q’s medical cost ratio is aggregated across states, so investors cannot isolate Illinois performance. The next evidence that would materially change the file would be a state-specific enrollee count, a contract start date, and a granular breakdown of Illinois medical cost ratios versus premium revenue. Until then, Illinois is a headline with a question mark, and the balance sheet remains the only fact on the table.